125 related articles for article (PubMed ID: 20501616)
21. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
22. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
[TBL] [Abstract][Full Text] [Related]
23. [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].
Chen JF; Jin J
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):890-3. PubMed ID: 20193325
[TBL] [Abstract][Full Text] [Related]
24. Pralatrexate: basic understanding and clinical development.
Zain J; O'Connor O
Expert Opin Pharmacother; 2010 Jul; 11(10):1705-14. PubMed ID: 20509772
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
26. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
27. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
[TBL] [Abstract][Full Text] [Related]
28. Pralatrexate pharmacology and clinical development.
Marchi E; Mangone M; Zullo K; O'Connor OA
Clin Cancer Res; 2013 Dec; 19(24):6657-61. PubMed ID: 23965902
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Jackson G; Einsele H; Moreau P; Miguel JS
Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
[TBL] [Abstract][Full Text] [Related]
31. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
32. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T; Barbarotta L; Foss F
Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.
Jain S; Jirau-Serrano X; Zullo KM; Scotto L; Palermo CF; Sastra SA; Olive KP; Cremers S; Thomas T; Wei Y; Zhang Y; Bhagat G; Amengual JE; Deng C; Karan C; Realubit R; Bates SE; O'Connor OA
Clin Cancer Res; 2015 May; 21(9):2096-106. PubMed ID: 25677697
[TBL] [Abstract][Full Text] [Related]
34. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Shimanovsky A; Dasanu CA
Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
[TBL] [Abstract][Full Text] [Related]
35. [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
Wang QW; Liu H; Liang YM; Wang T; Zhu XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jun; 43(6):456-9. PubMed ID: 18826102
[TBL] [Abstract][Full Text] [Related]
36. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
Jiang XX; Zhang QL; Chen XY; Wu WL; Shen ZX; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1215-9. PubMed ID: 19840453
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitizing properties of bortezomib depend on therapeutic schedule.
Labussière M; Pinel S; Vandamme M; Plénat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):892-900. PubMed ID: 21168283
[TBL] [Abstract][Full Text] [Related]
38. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.
Toner LE; Vrhovac R; Smith EA; Gardner J; Heaney M; Gonen M; Teruya-Feldstein J; Sirotnak F; O'Connor OA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):924-32. PubMed ID: 16467107
[TBL] [Abstract][Full Text] [Related]
39. Pralatrexate - from bench to bedside.
Zain JM; Marchi E
Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
[TBL] [Abstract][Full Text] [Related]
40. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
